Jiuzhou Pharma

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (Stock Abbreviation: Jiuzhou Pharma, Stock Code: 603456.SH), headquartered in Taizhou, Zhejiang, was established in 1998. Its predecessor was the Huangyan County Dongshan Monosodium Glutamate Factory founded in 1973 and was listed on the Shanghai Stock Exchange in 2014. It is a global leading CDMO enterprise for innovative drugs and a manufacturer of generic drugs.As one of the earlier enterprises in China to enter the CDMO field, Jiuzhou Pharma has actively ventured into the innovative drug CDMO sector since 2008, building a one-stop CDMO service business model while continuously consolidating its advantageous position in specialty active pharmaceutical ingredients in the global pharmaceutical market. It provides global pharmaceutical companies with high-quality, one-stop services covering the entire industrial chain from preclinical CMC of new drugs to clinical phases I, II, III, NDA, and commercialization. In recent years, the company has actively expanded its business layout through a combination of "self-construction + mergers and acquisitions," accelerating CDMO capacity construction to achieve rapid business expansion and strategic transformation.Jiuzhou Pharma has built internationally advanced production bases in Taizhou and Hangzhou, Zhejiang, Yancheng and Suzhou, Jiangsu. It has also established R&D centers in Hangzhou and Taizhou, Zhejiang, Nanjing, Jiangsu, and North Carolina, USA. The company owns industry-leading innovation platforms such as a national-level enterprise technology center, a national postdoctoral research workstation, and a CNAS-certified laboratory. Over the years, it has received honors such as National Technological Innovation Demonstration Enterprise, National Green Factory, and Top 10 CXO (including CDMO) Enterprises in China.Jiuzhou Pharma has over 800 global partners, including internationally renowned pharmaceutical companies such as Novartis, Roche, Zoetis, Gilead, and Daiichi Sankyo, as well as domestically prominent innovative pharmaceutical enterprises like Betta Pharmaceuticals, Hutchison MediPharma, Allecra Therapeutics, Haihe Biopharma, Luye Pharma, and Hua Medicine. It is one of the most trusted partners for global innovative drug development enterprises. Its CDMO projects cover therapeutic areas such as anti-cancer, anti-heart failure, anti-depression, anti-Parkinson's, anti-lung cancer, antiviral, anti-diabetes, and anti-respiratory infections.As a leader in green pharmaceutical innovation technology in China, Jiuzhou Pharma regards independent R&D innovation as the core driving force for enterprise development. It has built an efficient R&D innovation system, a systematic intellectual property protection system, and a comprehensive trade secret protection system. It has formed a high-level, professional, international R&D team and expert advisory team covering various academic fields. With years of new drug R&D and technological accumulation, Jiuzhou Pharma has mastered numerous cutting-edge green pharmaceutical technologies with independent intellectual property rights. It has established multiple leading technology platforms such as chiral catalysis, continuous processing, fluorine chemistry, enzymatic catalysis, photocatalysis, electrochemistry, crystallization, and peptide technology, providing industry-leading technical solutions to customers and promoting industrial upgrading and rapid development in the biopharmaceutical sector.